-

MVST Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Microvast Holdings, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Microvast Holdings, Inc. (NASDAQ: MVST) securities between April 1, 2025 and March 16, 2026. Microvast purports to design, develop, and manufacture “advanced specialized battery technologies”, primarily for use in electric commercial vehicles and energy storage systems (“ESS”).

Robbins LLP is Investigating Allegations that Microvast Holdings, Inc. (MVST) Misled Investors Regarding its Ability to Reach its Margin Targets

Share

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Microvast Holdings, Inc. (MVST) Misled Investors Regarding its Ability to Reach its Margin Targets.

According to the complaint, during the class period, defendants announced the expansion of its manufacturing facility located in Huzhou, China, dubbing the initiative “Huzhou Phase 3.2”, claiming that its increased production capacity would be online before the end of 2025. Defendants likewise advised investors to expect improved margins, touting a supposed “strategic repositioning away from low-margin segments” and a new “focus . . . towards more profitable, higher-value opportunities”. Notwithstanding, plaintiff alleges that defendants failed to disclose that (i) due to, inter alia, inventory management issues and delays in commercial vehicle rollouts by Microvast’s customers, defendants had overstated Microvast’s ability to reach its margin targets, and (ii) defendants overstated Microvast’s ability to complete the Huzhou Phase 3.2 expansion by the end of 2025.

A series of disclosures, after which Microvast's stock declined, revealed the truth about the Company. Microvast's final disclosure occurred on March 16, 2026, it reported its financial and operating results for the quarter and year ended December 31, 2025. Among other items, Microvast reported that gross margin declined to approximately 1% for the quarter, down sharply from approximately 36% for the same period in the prior year, which the Company attributed to inventory impairment charges arising from “specialized ESS components”. Microvast also reported revenue of $96.5 million for the quarter, representing a 15% year-over-year decrease and falling well short of the consensus estimate of $136.4 million. Microvast attributed this result to “regulatory shifts in South Korea and delays in customer platform ramp-up” in Europe, the Middle East, and Africa. On this news, Microvast’s stock price fell $0.79 per share, or 34.2%, to close at $1.52 per share on March 17, 2026.

What Now: You may be eligible to participate in the class action against Microvast Holdings, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $1 billion in value to shareholders, secured some of the largest recoveries in shareholder derivative litigation history, and achieved governance reforms at over 400 Fortune 1000 companies.

"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Microvast Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:MVST

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Stockholder Alert - Robbins LLP Informs Investors of the Datavault AI Inc. Class Action 

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Datavault AI Inc. Misled Investors Regarding its Business Prospects...

Investor Alert: Robbins LLP Informs Investors of the Alarum Technologies Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Alarum Technologies Ltd. (NASDAQ: ALAR) securities between March 20, 2025 and July 2, 2026 (the "Class Period"). Alarum contends to be global provider of web data collection solutions, empowering organizations to gain a competitive edge by streamlining the collection, extraction, and analysis of large-scale structured...

Shareholder Notice: Robbins LLP Informs Investors of the ARS Pharmaceuticals Inc. Class Action  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, inc...
Back to Newsroom